Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

about

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

Item

http://www.wikidata.org/entity/Q47111016

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@en

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@nl

type

Item

label

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@en

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@nl

prefLabel

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@en

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@nl

P1476

Phase I dose-finding study of ...... t cancer: JBCRG-18 cape study.

@en

P2093

Akiyo Yoshimura

http://www.w3.org/2001/XMLSchema#string

Hiroji Iwata

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ishiguro

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Yasojima

http://www.w3.org/2001/XMLSchema#string

Masaya Hattori

http://www.w3.org/2001/XMLSchema#string

Norikazu Masuda

http://www.w3.org/2001/XMLSchema#string

Satoshi Morita

http://www.w3.org/2001/XMLSchema#string

Shinji Ohno

http://www.w3.org/2001/XMLSchema#string

Shoichiro Ohtani

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.

Tumour lysis syndrome: new therapeutic strategies and classification.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials

P2888

s12282-017-0798-4

P304

108-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-017-0798-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28861862

http://www.w3.org/2001/XMLSchema#string

P932

5741785

http://www.w3.org/2001/XMLSchema#string